| Editors |
|
xi | |
| List of Contributors |
|
xiii | |
| Foreword |
|
xix | |
| Preface |
|
xxi | |
| 1 Introduction to Lung Physiology from a Drug Delivery Perspective |
|
1 | (12) |
|
|
|
|
|
|
|
|
| 2 Introduction to Pharmacology of the Lung from a Drug Delivery Perspective |
|
13 | (16) |
|
|
|
|
| 3 Mechanism and Ways of Pulmonary Drug Administration |
|
29 | (12) |
|
|
|
|
|
|
| 4 Transepithelial Route of Drug Delivery through the Pulmonary System |
|
41 | (12) |
|
|
|
|
| 5 Understanding the Pharmacokinetics and Pharmacodynamics of Lung and Lung Drug Delivery |
|
53 | (8) |
|
|
| 6 Chronic Lung Diseases: Treatment, Challenges, and Solutions |
|
61 | (12) |
|
|
|
|
|
|
|
|
|
|
| 7 Understanding of Lung Diseases with a Focus on Applications of Nano-particulate Drug Delivery Systems |
|
73 | (18) |
|
|
|
|
|
|
|
|
|
|
| 8 Model for Pharmaceutical Aerosol Transport through Stenosis Airway |
|
91 | (38) |
|
|
|
|
|
|
|
|
|
|
|
|
| 9 Design of Efficient Dry Powder Inhalers |
|
129 | (26) |
|
|
|
|
|
|
|
|
| 10 In Vivo Animal Models for Lung Targeted Drug Delivery Systems |
|
155 | (6) |
|
|
|
|
|
|
| 11 Advances in In Silico Study of Generic Orally Inhaled Drug Products |
|
161 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 12 Effect of Aerosol Devices and Administration Techniques on Drug Delivery in a Simulated Spontaneously Breathing Pediatric Tracheostomy Model |
|
171 | (10) |
|
|
|
|
| 13 Pulmonary Drug Delivery: The Role of Polymeric Nanoparticles |
|
181 | (12) |
|
|
|
|
|
|
|
|
|
|
| 14 Polymeric Nanoparticle-Based Drug-Gene Delivery for Lung Cancer |
|
193 | (16) |
|
|
|
|
|
|
|
|
| 15 Inhalable Polymeric Nano-particulate Powders for Respiratory Delivery |
|
209 | (16) |
|
|
|
|
| 16 Recent Trends in Applications of Nano-Drug Delivery Systems |
|
225 | (14) |
|
|
|
|
|
|
|
|
| 17 Nanocarrier Systems for Lung Drug Delivery |
|
239 | (18) |
|
|
|
|
| 18 Nanomedicine for the Management of Pulmonary Disorders |
|
257 | (16) |
|
|
|
|
|
|
|
|
| 19 Recent Approaches in Dendrimer-Based Pulmonary Drug Delivery |
|
273 | (14) |
|
|
|
|
| 20 Hybrid Lipid/Polymer Nanoparticles for Pulmonary Delivery of siRNA: Development and Fate Upon In Vitro Deposition on the Human Epithelial Airway Barrier |
|
287 | (16) |
|
|
|
|
|
|
| 21 Solid Lipid Nanoparticle-Based Drug Delivery for Lung Cancer |
|
303 | (22) |
|
|
|
|
|
|
|
|
| 22 Lipid-Based Pulmonary Delivery System: A Review and Future Considerations of Formulation Strategies and Limitations |
|
325 | (12) |
|
|
|
|
| 23 Respirable Controlled Release Polymeric Colloidal Nanoparticles |
|
337 | (16) |
|
|
|
|
| 24 Lung Clearance Kinetics of Liposomes and Solid Lipid Nanoparticles |
|
353 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 25 Solid Lipid Nanoparticles for Sustained Pulmonary Delivery of Herbal Drugs for Lung Delivery: Preparation, Characterization, and In Vivo Evaluation |
|
361 | (26) |
|
|
|
|
|
|
| 26 Improved Solid Lipid Nano-formulations for Pulmonary Delivery of Paclitaxel for Lung Cancer Therapy |
|
387 | (22) |
|
|
|
|
|
|
|
|
| 27 Anti-angiogenic Therapy for Lung Cancer: Focus on Bioassay Development in a Quest for Anti-VEGF Drugs |
|
409 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
| 28 Emerging Applications of Nanoparticles for Lung Cancer Diagnosis and Therapy |
|
423 | (10) |
|
|
|
|
|
|
|
|
| 29 Metallic Nanoparticles: Technology Overview and Drug Delivery Applications in Lung Cancer |
|
433 | (10) |
|
|
|
|
| 30 Modeling of Pharmaceutical Aerosol Transport in the Targeted Region of Human Lung Airways Due to External Magnetic Field |
|
443 | (16) |
|
|
|
|
|
|
|
|
|
|
| 31 Phytochemicals and Biogenic Metallic Nanoparticles as Anti-cancer Agents in Lung Cancer |
|
459 | (12) |
|
|
|
|
|
|
| 32 Pulmonary Applications and Toxicity of Engineered Metallic Nanoparticles |
|
471 | (12) |
|
|
| 33 Anti-cancer Activity of Eco-friendly Gold Nanoparticles against Lung and Liver Cancer Cells |
|
483 | (14) |
|
|
|
|
| 34 Sub-chronic Inhalational Toxicity Studies for Gold Nanoparticles |
|
497 | (6) |
|
|
|
|
| 35 Single-Use Dry Powder Inhalers for Pulmonary Drug Delivery |
|
503 | (10) |
|
|
|
|
| 36 Lung Delivery of Nicotine for Smoking Cessation |
|
513 | (14) |
|
|
|
|
| 37 Formulation and Characterization of Dry Powder Inhalers for Pulmonary Drug Delivery |
|
527 | (12) |
|
|
|
|
|
|
| 38 Devices for Dry Powder Drug Delivery to the Lung |
|
539 | (10) |
|
|
|
|
|
|
|
|
| 39 Numerical Modeling of Agglomeration and De-agglomeration in Dry Powder Inhalers |
|
549 | (8) |
|
|
|
|
| 40 Oronasal and Tracheostomy Delivery of Soft Mist and Pressurized Metered-Dose Inhalers with Valved Holding Chamber |
|
557 | (18) |
|
|
|
|
|
|
| 41 Modeling for Biopharmaceutical Performance in Lung Drug Discovery |
|
575 | (4) |
|
|
|
|
|
|
|
|
| 42 Regulatory Consideration for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India |
|
579 | (12) |
|
|
|
|
| 43 Regulatory Perspectives and Concerns Related to Nanoparticle-Based Lung Delivery |
|
591 | (20) |
|
|
|
|
|
|
|
Pompy Patowary Pronobesh Chattopadhyay |
|
|
|
|
|
| 44 Clinical Controversies of Pediatric Aerosol Therapy |
|
611 | (12) |
|
|
|
|
| 45 Drug Delivery Using Aerosols: Challenges and Advances in Neonatal Pediatric Subgroup |
|
623 | (8) |
|
|
|
|
|
|
| 46 Safety and Toxicological Concerns Related to Nanoparticle-Based Lung Delivery |
|
631 | (12) |
|
|
|
|
|
|
|
|
| 47 Nanoparticle-Based Lung Drug Delivery: A Clinical Perspective |
|
643 | (10) |
|
|
|
|
| 48 European Perspective on Orally Inhaled Products: In Vitro Requirements for a Biowaiver |
|
653 | (8) |
|
|
|
|
|
|
|
|
| Index |
|
661 | |
More info about Taylor & Francis e-books